Pharvaris N.V. (NASDAQ:PHVS) Receives $41.70 Consensus Target Price from Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS) have earned an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $41.70.

Several research firms recently issued reports on PHVS. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, March 3rd. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a report on Wednesday, November 19th. Morgan Stanley boosted their price target on Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a research note on Thursday, December 4th. Bank of America upped their price target on Pharvaris from $27.00 to $30.00 and gave the company a “neutral” rating in a report on Thursday, December 4th. Finally, Oppenheimer lifted their price objective on Pharvaris from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th.

Pharvaris Trading Down 3.6%

Shares of NASDAQ PHVS opened at $25.42 on Friday. The firm’s 50 day moving average price is $26.69 and its 200-day moving average price is $24.99. Pharvaris has a 52-week low of $11.51 and a 52-week high of $29.80.

Institutional Trading of Pharvaris

A number of large investors have recently made changes to their positions in PHVS. Geode Capital Management LLC raised its holdings in shares of Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after purchasing an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the last quarter. Legal & General Group Plc grew its position in Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares during the period. Amundi grew its position in Pharvaris by 2,741,600.0% in the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after purchasing an additional 27,416 shares during the period. Finally, HighVista Strategies LLC raised its stake in Pharvaris by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock valued at $418,000 after buying an additional 971 shares during the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.